NZ630810A - Processes and intermediates for the preparation of a pde10 inhibitor - Google Patents

Processes and intermediates for the preparation of a pde10 inhibitor

Info

Publication number
NZ630810A
NZ630810A NZ630810A NZ63081014A NZ630810A NZ 630810 A NZ630810 A NZ 630810A NZ 630810 A NZ630810 A NZ 630810A NZ 63081014 A NZ63081014 A NZ 63081014A NZ 630810 A NZ630810 A NZ 630810A
Authority
NZ
New Zealand
Prior art keywords
preparation
intermediates
processes
pde10 inhibitor
pde10
Prior art date
Application number
NZ630810A
Other languages
English (en)
Inventor
Michael James Mcdermott
Marco Jonas
Jennifer Lynn Gage
Elisabeth C A Brot
Thomas L Little
Neil S Cutshall
Karl E Reineke
Wayne Douglas Luke
Original Assignee
Omeros Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Omeros Corp filed Critical Omeros Corp
Priority to NZ716494A priority Critical patent/NZ716494A/en
Publication of NZ630810A publication Critical patent/NZ630810A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/40—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F1/00—Compounds containing elements of Groups 1 or 11 of the Periodic Table
    • C07F1/02—Lithium compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F19/00—Metal compounds according to more than one of main groups C07F1/00 - C07F17/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F3/00—Compounds containing elements of Groups 2 or 12 of the Periodic Table
    • C07F3/02—Magnesium compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Materials Engineering (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Furan Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
NZ630810A 2014-04-28 2014-09-10 Processes and intermediates for the preparation of a pde10 inhibitor NZ630810A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ716494A NZ716494A (en) 2014-04-28 2014-09-10 Processes and intermediates for the preparation of a pde10 inhibitor

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461985400P 2014-04-28 2014-04-28

Publications (1)

Publication Number Publication Date
NZ630810A true NZ630810A (en) 2016-03-31

Family

ID=54359190

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ630810A NZ630810A (en) 2014-04-28 2014-09-10 Processes and intermediates for the preparation of a pde10 inhibitor
NZ716494A NZ716494A (en) 2014-04-28 2014-09-10 Processes and intermediates for the preparation of a pde10 inhibitor

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ716494A NZ716494A (en) 2014-04-28 2014-09-10 Processes and intermediates for the preparation of a pde10 inhibitor

Country Status (13)

Country Link
US (2) US9650368B2 (OSRAM)
EP (1) EP3137462B1 (OSRAM)
JP (1) JP6474430B2 (OSRAM)
KR (1) KR102496552B1 (OSRAM)
CN (1) CN106459026B (OSRAM)
AU (1) AU2015253464B2 (OSRAM)
BR (1) BR112016025287B1 (OSRAM)
CA (1) CA2946756C (OSRAM)
ES (1) ES2723437T3 (OSRAM)
IL (1) IL248585B (OSRAM)
NZ (2) NZ630810A (OSRAM)
RU (1) RU2718863C2 (OSRAM)
WO (1) WO2015167969A1 (OSRAM)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2544679B1 (en) * 2010-03-12 2019-05-15 Omeros Corporation Pde10 inhibitors and related compositions and methods
NZ716462A (en) * 2014-04-28 2017-11-24 Omeros Corp Optically active pde10 inhibitor
CA3003611C (en) 2015-11-04 2022-11-01 Omeros Corporation Solid state forms of a pde10 inhibitor

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK178590D0 (da) 1990-07-26 1990-07-26 Novo Nordisk As 1,4-disubstituerede piperaziner
PT100905A (pt) 1991-09-30 1994-02-28 Eisai Co Ltd Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem
CA2400368A1 (en) 1992-12-02 1994-06-09 Allen J. Duplantier Catechol diethers as selective pde iv inhibitors
DE4323192A1 (de) 1993-07-10 1995-01-12 Basf Ag Verfahren zur Herstellung von Homo- und Copolymerisaten von Alk-1-enen
DE4325846C1 (de) 1993-07-31 1995-01-19 Herberts Gmbh Verwendung von Furan-modifizierten aromatischen Pinakolderivaten als Initiatoren und Furan-modifizierte aromatische Pinakolderivate als solche
DE4343286A1 (de) 1993-12-17 1995-06-22 Hoechst Ag Heteroaromatische Verbindungen und ihre Verwendung in flüssigkristallinen Mischungen
DE4409501A1 (de) 1994-03-19 1995-09-21 Didier Werke Ag Verschleißfutter eines Schachtofens und Stein hierfür
EP0766676B1 (en) 1994-06-24 2002-05-22 Euroceltique S.A. Compounds for inhibiting phosphodiesterase iv
US5789434A (en) 1994-11-15 1998-08-04 Bayer Corporation Derivatives of substituted 4-biarylbutyric acid as matrix metalloprotease inhibitors
TW332201B (en) 1995-04-06 1998-05-21 Janssen Pharmaceutica Nv 1,3-Dihydro-1-(phenylalkyl)-2H-imidazol-2-one derivatives
TW424087B (en) 1995-04-06 2001-03-01 Janssen Pharmaceutica Nv 1,3-dihydro-1-(phenylalkenyl)-2H-imidazol-2-one derivatives
US6037370A (en) 1995-06-08 2000-03-14 Vertex Pharmaceuticals Incorporated Methods and compositions for stimulating neurite growth
ATE216384T1 (de) 1996-01-22 2002-05-15 Fujisawa Pharmaceutical Co Thiazolylbenzofuranderivate und pharmazeutische zusammensetzungen die sie enthalten
WO1998008830A1 (de) 1996-08-26 1998-03-05 Byk Gulden Lomberg Chemische Fabrik Gmbh Thiazol-derivate als selektive inhibitoren der pde-iv
JPH1087543A (ja) 1996-09-17 1998-04-07 Chisso Corp アルコキシベンゼン誘導体、液晶組成物および液晶表示素子
US6548490B1 (en) 1997-10-28 2003-04-15 Vivus, Inc. Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
WO1999045914A1 (en) 1998-03-13 1999-09-16 Maruho Kabushikikaisha Alkyl amine derivative and local anesthetic agent using the same
GB9807354D0 (en) 1998-04-07 1998-06-03 Glaxo Group Ltd Antiviral compound
SE9804212D0 (sv) 1998-12-04 1998-12-04 Astra Pharma Prod Compounds
HUP0202248A3 (en) 1999-03-12 2006-06-28 Boehringer Ingelheim Pharma Compounds useful as anti-inflammatory agents
US7141593B1 (en) 1999-06-04 2006-11-28 Abbott Laboratories Pharmaceutical formulations
GB9929552D0 (en) 1999-12-14 2000-02-09 Proteus Molecular Design Compounds
AU2001269876A1 (en) 2000-06-15 2001-12-24 Mark Laurence Boys Heteroarylalkanoic acids as integrin receptor antagonists
US20030032579A1 (en) 2001-04-20 2003-02-13 Pfizer Inc. Therapeutic use of selective PDE10 inhibitors
EP1390377B1 (en) 2001-05-22 2006-03-08 Pfizer Products Inc. New crystal form of azithromycin
EP1499662A1 (en) * 2002-04-18 2005-01-26 Avecia Limited Prepation of a conjugated molecule and materials for use therein
US6821502B2 (en) 2002-06-12 2004-11-23 Chevron U.S.A. Inc. Method of making aluminum-containing zeolite with IFR structure
CA2494668A1 (en) 2002-07-27 2004-02-05 Astrazeneca Ab Chemical compounds
EA008767B1 (ru) 2002-10-08 2007-08-31 Зе Скрипс Ресеч Инститьют Ингибиторы гидролазы амидов жирных кислот
NZ540167A (en) 2002-10-30 2007-06-29 Neuro3D Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses
TW200410921A (en) 2002-11-25 2004-07-01 Hoffmann La Roche Mandelic acid derivatives
JP4464280B2 (ja) 2002-12-06 2010-05-19 興和株式会社 エリスロポエチン産生促進剤
WO2004058254A1 (en) 2002-12-20 2004-07-15 Pharmacia Corporation Heteroarylalkanoic acids as integrin receptor antagonists
WO2004071509A1 (ja) 2003-02-12 2004-08-26 Nippon Chemiphar Co., Ltd. オリゴデンドロサイト分化促進剤
WO2004094411A1 (en) 2003-04-18 2004-11-04 Memory Pharmaceuticals Corporation Pyrazole derivatives as phosphodiesterase 4 inhibitors
AR047541A1 (es) 2004-02-13 2006-01-25 Sandoz Ag Fosfato de 5-[[4-[2-metil-2-piridinil-amino-etoxi]fenil]metil]-2,4 tiazolidinadiona (rosiglitazona) y sus formas polimorficas
JP4879165B2 (ja) 2004-04-20 2012-02-22 トランス テック ファーマ，インコーポレイテッド メラノコルチン受容体の調節因子としての置換チアゾール及びピリミジン誘導体
MXPA06013250A (es) * 2004-05-14 2007-02-28 Abbott Lab Inhibidores de quinasa como agentes terapeuticos.
US7351833B2 (en) 2004-07-23 2008-04-01 Abbott Laboratories (1S,5S)-3-(5,6-dichloropyridin-3-yl)-3,6-diazabicyclo[3.2.0]heptane benzenesulfonate
US7449486B2 (en) * 2004-10-19 2008-11-11 Array Biopharma Inc. Mitotic kinesin inhibitors and methods of use thereof
US8436176B2 (en) 2004-12-30 2013-05-07 Medicis Pharmaceutical Corporation Process for preparing 2-methyl-1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine
CN101098866A (zh) 2005-01-07 2008-01-02 辉瑞产品公司 杂芳族喹啉化合物及其作为pde10抑制剂的用途
BRPI0607006B1 (pt) 2005-02-04 2017-05-16 Senomyx Inc compostos que compreendem funções orgânicas de hetero arilas ligadas e seus usos como novos modificadores, flavorizantes e promotores do sabor umami para composições comestíveis
CA2605603A1 (en) 2005-04-22 2006-11-02 Kalypsys, Inc. Ortho-terphenyl inhibitors of p38 kinase and methods of treating inflammatory disorders
UA91546C2 (uk) 2005-05-03 2010-08-10 Бьорінгер Інгельхайм Інтернаціональ Гмбх КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ
MY152185A (en) 2005-06-10 2014-08-29 Novartis Ag Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation
JP2009503107A (ja) 2005-08-04 2009-01-29 アポジー・バイオテクノロジー・コーポレイション スフィンゴシンキナーゼ阻害剤およびそれらの使用方法
KR20080050577A (ko) 2005-08-29 2008-06-09 사노피-아벤티스 유.에스. 엘엘씨 피리다지노[4,5-ｂ]인돌 유도체의 신규 결정질 형태
JP2008522983A (ja) 2005-09-13 2008-07-03 シコール インコーポレイティド ロクロニウムブロミドの合成方法
US8637559B2 (en) 2005-11-15 2014-01-28 Otsuka Pharmaceutical Co., Ltd. Oxazole compound and pharmaceutical composition
US20080312305A1 (en) 2005-12-23 2008-12-18 Udo Bauer Imidazoles as Gaba- B Receptor Modulators
US20090176829A1 (en) 2006-05-02 2009-07-09 Pfizer Inc Bicyclic heteroaryl compounds as pde10 inhibitors
US20080090834A1 (en) 2006-07-06 2008-04-17 Pfizer Inc Selective azole pde10a inhibitor compounds
AU2007292247A1 (en) 2006-09-08 2008-03-13 Ore Pharmaceuticals Inc. Method for reducing or alleviating inflammation in the digestive tract
SI2076501T1 (sl) 2006-09-25 2016-05-31 Ptc Therapeutics, Inc. Kristalinične oblike 3-(5-(2-florofenil)-1,2,4) oksadiazol-3-il)-benzojske kisline
EP2436382A1 (en) 2006-09-28 2012-04-04 Merck Sharp & Dohme Corporation Pharmaceutical compositions of HDAC inhibitors and chelatable metal compounds, and metal-HDAC inhibitor chelate complexes
WO2008040669A2 (en) 2006-10-02 2008-04-10 Janssen Pharmaceutica N.V. Novel intermediates for the preparation of a glyt1 inhibitor
US7837978B2 (en) 2006-10-13 2010-11-23 Chevron U.S.A. Inc. Process for preparing aluminum-containing molecular sieve SSZ-26
US7786139B2 (en) 2006-11-21 2010-08-31 Omeros Corporation PDE10 inhibitors and related compositions and methods
WO2008064342A2 (en) 2006-11-21 2008-05-29 Omeros Corporation Pde10 inhibitors and related compositions and methods
PE20081506A1 (es) 2006-12-12 2008-12-09 Infinity Discovery Inc Formulaciones de ansamicina
WO2009008906A2 (en) 2007-02-06 2009-01-15 The Trustees Of The University Of Pennsylvania Therapeutic compounds for blocking dna synthesis of pox viruses
EP2160394A1 (en) 2007-05-22 2010-03-10 Ultimorphix Technologies B.v. Tenofovir disoproxil hemi-fumaric acid co-crystal
EP2017264A1 (de) 2007-07-16 2009-01-21 Bayer Cropscience Ag Substituierte Phenylpropargylverbindungen, Verfahren zu deren Herstellung und deren Verwendung als Herbizide und Pflanzenwachstumsregulatoren
WO2009049022A1 (en) 2007-10-10 2009-04-16 Ore Pharmaceuticals Inc. Method for treatment of pancreatitis
TW200944520A (en) 2008-01-29 2009-11-01 Glaxo Group Ltd Spiro compounds as NPY Y5 receptor antagonists
WO2009143178A2 (en) 2008-05-20 2009-11-26 Omeros Corporation Pde10 inhibitors and related compositions and methods
TWI501965B (zh) 2008-06-20 2015-10-01 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑之新穎苯基咪唑衍生物
EP2310016B1 (en) 2008-08-05 2017-10-04 Omeros Corporation Pde10 inhibitors and related compositions and methods
EP2544679B1 (en) 2010-03-12 2019-05-15 Omeros Corporation Pde10 inhibitors and related compositions and methods
NZ716462A (en) * 2014-04-28 2017-11-24 Omeros Corp Optically active pde10 inhibitor

Also Published As

Publication number Publication date
RU2718863C2 (ru) 2020-04-15
US20180057484A1 (en) 2018-03-01
EP3137462A1 (en) 2017-03-08
IL248585A0 (en) 2016-12-29
WO2015167969A1 (en) 2015-11-05
AU2015253464A1 (en) 2016-10-27
BR112016025287B1 (pt) 2022-10-11
IL248585B (en) 2020-03-31
CA2946756C (en) 2022-03-29
KR102496552B1 (ko) 2023-02-06
JP2017513885A (ja) 2017-06-01
RU2016146118A (ru) 2018-05-30
ES2723437T3 (es) 2019-08-27
US9650368B2 (en) 2017-05-16
JP6474430B2 (ja) 2019-02-27
CA2946756A1 (en) 2015-11-05
CN106459026B (zh) 2019-07-05
AU2015253464B2 (en) 2018-11-22
US20160024069A1 (en) 2016-01-28
RU2016146118A3 (OSRAM) 2018-12-24
CN106459026A (zh) 2017-02-22
EP3137462A4 (en) 2017-12-27
NZ716494A (en) 2017-07-28
KR20160147275A (ko) 2016-12-22
BR112016025287A2 (pt) 2017-08-15
EP3137462B1 (en) 2019-01-30

Similar Documents

Publication Publication Date Title
IL282468A (en) 2- amino-n-heteroaryl-nicotinamides as nav1.8 inhibitors
LT3710446T (lt) Junginiai, naudingi cdk7 slopinimui
IL266214B (en) 5,4,2-tri-converted 4,2,1-triazolones used as dhodh inhibitors
NZ724645A (en) Pde10 inhibitors and related compositions and methods
CO2017002714A2 (es) Ácido 4-(3-fluoro-3-(2-(5,6,7,8-tetrahidro-1,8-naftiridin-2-il)etil)pirrolidin-1-il)-3-(3-(2-metoxietoxi)fenil)butanoico, o una sal del mismo
CU20170057A7 (es) Derivados de feniltriazol sustituido con hidroxialquilo
PH12016501388A1 (en) Heteroaryls and uses thereof
EA201691625A1 (ru) Ароматические гетероциклические соединения как противовоспалительные соединения
IL252981B (en) History of 5-[(piperazine-1-yl)-3-oxo-propyl]-imidazolidine-4,2-dione as adamts inhibitors for the treatment of osteoarthritis
SI3464265T1 (sl) Polimorfi N-((3-fluoro-4-metoksipiridin-2-IL)metil)-3-(metoksimetil)- 1-((4-(2-oksopiridin-1-IL)metil)fenil)pirazol-4-karboksamida kot zaviralci kalikreina
PH12017502051A1 (en) TBK/IKKe INHIBITOR COMPOUNDS AND USES THEREOF
NZ742952A (en) Methods for the preparation of 1,3-benzodioxole heterocyclic compounds
IL256237A (en) Solid forms of (z)-4-(5-((3-benzyl-4-oxo-2-thioxothiazolidin-5-ylidene)methyl)furan-2-yl)benzoic acid
EA201790983A1 (ru) Синтез копанлисиба и его дигидрохлорида
TW201613934A (en) Methods for the preparation of 1,3-benzodioxole heterocyclic compounds
MX394835B (es) Metodos para la preparacion de compuestos heterociclicos de 1,3-benzodioxol.
HK1223367A1 (zh) 新型dgat2抑制劑
CL2017000484A1 (es) Compuestos de azetidiniloxifenilpirrolidina
MA39824A (fr) Composés azole amido-substitués
ZA202003028B (en) Novel use of 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative
NZ630803A (en) Optically active pde10 inhibitor
NZ630810A (en) Processes and intermediates for the preparation of a pde10 inhibitor
IL272992A (en) Solid structures of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-N-benzylacetamide
PH12016500017A1 (en) New salt of 3-[(3-{[4-(4-morpholinylmethyl)-1h-pyrrol-2-yl]methylene}-2-oxo-2,3-dihydro-1h-indol-5-yl)methyl]-1,3-thiazolidine-2,4-dione, its preparation, and formulations containing it
PH12017500123A1 (en) Crystal of azole benzene derivative

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 SEP 2019 BY COMPUTER PACKAGES INC

Effective date: 20180818

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 SEP 2020 BY COMPUTER PACKAGES INC

Effective date: 20190820

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 SEP 2021 BY COMPUTER PACKAGES INC

Effective date: 20200818

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 SEP 2022 BY COMPUTER PACKAGES INC

Effective date: 20210817

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 SEP 2023 BY COMPUTER PACKAGES INC

Effective date: 20220817

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 SEP 2024 BY COMPUTER PACKAGES INC

Effective date: 20230817

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 SEP 2025 BY COMPUTER PACKAGES INC

Effective date: 20240817

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 SEP 2026 BY COMPUTER PACKAGES INC

Effective date: 20250817